Inflammatory bone loss: pathogenesis and therapeutic intervention

被引:0
作者
Kurt Redlich
Josef S. Smolen
机构
[1] Medical University of Vienna,Division of Rheumatology, Department of Medicine 3
来源
Nature Reviews Drug Discovery | 2012年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Bone homeostasis is dependent on the concerted actions of bone-building osteoblasts and bone-degrading osteoclasts — a process called bone remodelling.Two of the major factors that induce osteoblast differentiation and activation are: the signalling mediated by bone morphogenetic proteins via runt-related transcription factor 2; and the WNT–Frizzled–β-catenin pathway. Conversely, Dickkopf-related protein 1 (DKK1) and sclerostin inhibit osteoblast activation.Major molecules involved in osteoclast differentiation and activation include macrophage colony-stimulating factor and receptor activator of nuclear factor-κB (RANK) as well as its ligand (RANKL).Inflammation is associated with the overproduction of various cytokines, such as tumour necrosis factor, interleukin-1 (IL-1), IL-6 or IL-17. Their upregulation in the course of inflammation leads to excessive bone degradation mainly due to hyperactivation of osteoclasts, although some cytokines can also impair osteoblast function.Many diseases lead to inflammatory bone loss, including inflammatory bowel disease, chronic obstructive lung disease, cystic fibrosis, periodontitis, rheumatoid arthritis and other inflammatory diseases.Inflammatory bone loss is always systemic, and in some diseases — such as rheumatoid arthritis or periodontitis — it can also involve local bone.Therapies interfering with inflammation also affect systemic inflammatory bone loss, primarily by reducing the effects of cytokines on osteoclast activation; however, many of these treatments will not fully control inflammation. Owing to this ongoing inflammatory activity (even at low levels), bone loss will continue to accrue and therefore also requires specific targeting of bone cells.Bisphosphonates and denosumab are among the bone-targeting therapies that have been shown to be effective in treating inflammatory bone loss, but it is assumed that blockers of DKK1 and sclerostin — which are upregulated by cytokines and inhibit osteoblast repair mechanisms — are also likely to be effective.
引用
收藏
页码:234 / 250
页数:16
相关论文
共 516 条
[111]  
Karin M(1993)Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells Clin. Exp. Immunol. 94 145-98
[112]  
Koga T(1999) and a circulating TNF-like activity in rabbits J. Biol. Chem. 274 30919-1418
[113]  
Takayanagi H(1991)Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular signal-related kinase in upregulation of matrix metalloproteinase and ADAMTS gene expression in articular chondrocytes Eur. Cytokine Netw. 2 89-622
[114]  
Delaisse JM(1984)Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown N. Engl. J. Med. 311 1413-746
[115]  
Supanchart C(1993)The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells Perspect. Biol. Med. 36 611-3823
[116]  
Kornak U(1988)Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts Eur. J. Immunol. 18 739-5049
[117]  
Goldring SR(1990)Cytokine control of acute phase protein expression Mol. Cell Biol. 10 3818-399
[118]  
Roelke MS(1994)Interleukin-1 and the pathogenesis of the acute-phase response J. Immunol. 152 5041-144
[119]  
Petrison KK(1998)Regulation of the acute phase response by cytokines J. Bone Miner. Res. 13 393-166
[120]  
Bhan AK(2004)Action of recombinant human interleukin 6, interleukin 1β and tumor necrosis factor α on the mRNA induction of acute-phase proteins Cytokine 26 138-286